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Abstract 
Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin´s lymphoma found in oral and 
maxillofacial regions. A large number of cases may be biologically heterogeneous, which are commonly defined as 
DLBCL, not otherwise specified (NOS) by the World Health Organization (WHO-2008). The present case reports 
on an ulcer of raised and irregular edges, found on the border between the hard and soft palate, as the first and only 
manifestation of an extranodal non-Hodgkin lymphoma in an 85-year-old patient. Incisional biopsy was carried 
out, and the specimen revealed a proliferation of large lymphoid cells suggestive of diffuse large cell lymphoma. An 
immunohistochemical analysis was performed. EBV-RNA was assessed by in situ hybridization that also proved 
to be negative. Immunohistochemical and EBV analyses are important to avoid delays and inappropriate treatment 
strategies. Although advanced age is considered an adverse prognostic factor, early diagnosis did prove to be a key 
contributory factor in the cure of non-Hodgkin lymphoma. 
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most 
frequent type of non-Hodgkin´s lymphoma (NHL) 
found in the maxillofacial region (1-4). DLBLC affects 
both the osseous and soft tissues, and favored sites inclu-
de tonsils, palate, and parotid glands (3). Patients most 
commonly present a quick, painless swelling; in up to 
40% of patients, an extranodal site can also be identi-
fied (5,6), including oral tissues (3). The incidence of 
DLBCL oral lesions increases with age, occurring, on 
average, in the 7th and 8th decades of life (2,3). The etio-
logy remains unknown, and the immune deficiency is 
considered a risk factor (5). It is considered an aggressi-
ve but treatable neoplasm, with a variable clinical course 
(5,7).
DLBCL is a proliferation of large B lymphoid cells 
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with nuclear sizes equal to or exceeding the macropha-
ge nuclei or more than twice the size of a lymphocyte 
(8). Authors have subdivided DLBCL in distinct disea-
se entities according to morphological, biological, and 
clinical features. Variability in response to treatment is 
often observed, emphasizing the diversity of this disea-
se (5,9). The World Health Organization (WHO-2008) 
defines the cases in which there are no clear and accep-
ted criteria for the subdivision of DLBCL, not otherwise 
specified (NOS) (8,10). In addition, a distinct subgroup 
of DLBCL was identified as Age-related Epstein–Barr 
virus (EBV) associated diseases that appear to occur 
most often at advanced ages, namely EBV-associated 
B cell lymphoproliferative disorders (11,12). Thus, the 
investigation of EBV infection is important in elderly 
patients that present DLBCL without the association of 
disease immunosuppression. In this light, this workai-
med to present a case report of DLBCL-NOS of the pa-
late oral cavity in an elderly patient, as well as to carry 
out a review of the relevant literature.
Case report
An 85-year-old woman was referred to the Oral Medi-
cine Clinic of the School of Dentistry at Universidade 
Federal de Minas Gerais (UFMG) for evaluation of a 
lesion on the palate, with a two-weekevolution and com-
plaints of pain. Intraoral examination identified an ulcer 
of raised and irregular edges, measuring 30 mm at its lar-
gest diameter, covered by a yellowish-white membrane, 
located on the border of the hard and soft palate on the 
left side (Fig. 1). The patient was reportedly hypertensi-
ve, presented diastolic heart dysfunction, and had episo-
des of dizziness. Panoramic radiographsshowed no bone 
changes (Fig. 1). The differential clinical diagnoses in-
cluded a malignant neoplasm of miscellaneous origin or 
oral metastasis. An incisional biopsy was carried out,and 
the H&E stained specimen revealed a proliferation of 
large lymphoid cells with a high nucleus:cytoplasm ra-
tio, coarse chromatin, and inconspicuous nucleoli with 
abnormal mitotic figures (Fig. 2). The morphology was 
suggestive of diffuse large cell lymphoma and an im-
munohistochemical analysis was performed. Positive 
neoplastic cells for anti-CD20 (Fig. 2), CD79a, CD10, 
MUM-1, Bcl-6, and Bcl-2, as well as a labeling index 
of 90% for Ki-67 (Fig. 2), could be observed. Neoplas-
tic cells were negative for anti-CD3, CD5, and CD138. 
The EBV RNA assessed by in situ hybridization using 
EBER oligonucleotides proved to be negative. Immuno-
histochemicalanalysis of the EBV-latent gene products 
using latent membrane protein-1 (LMP-1) also proved 
to be negative. The diagnosis was of DLBCL-NOS. The 
patient was then referred to a physician. Computerized 
tomography scans of the chest, abdomen, and pelvis, 
and an iliac crest bone biopsy showed no signs of le-
sions. Signs of the involvement of nodal sites were not 
observed. The employed chemotherapy treatment was 
that of the R-CHOP protocol, applied every 21 days, 
over a three-month period (Rituximab - 500 mg D1; 
Cyclophosphamide - 800mg D; Vincristine - 1.0 mg 
D1, and prednisone - 80g D1-D5). After the 4th cycle 
of chemotherapy, the patient was referred for radiothe-
rapy. Radiotherapy treatment was 4320 cGy in lateral 
cervical facias, biopostos, and parallel fields, as well as 
the 4320 cGy indirect field under supraclavicular fossa, 
for 25 days. Total clinical resolution of the lesion after 
treatment could be observed.  After follow-up carried 
out for thirty-one months after treatment, the patient can 
now be considered clinically and radiographically free 
of disease (Fig. 1).
Fig. 1. A) Initial clinical image. An ulcer of raised and irregular edges 
could be observed on the border of the hard and soft palates. B) Ini-
tial panoramic radiographshowed no bone changes. C) Clinical image 
and D) panoramic radiograph after thirty-one months of diagnosis and 
treatment, in which the lesion’s total clinical resolution could be ob-
served. 
Fig. 2. Histopathological sections stained with hematoxylin-eosin 
show a neoplastic proliferation of large lymphoid cells (A, 50x original 
magnification) and the presence of neoplastic cells with coarse chro-
matin and inconspicuous nucleoli (B, 400x original magnification). 
Immunopositive cells of anti-CD20 (C, 400x original magnification, 
Streptoavidin-biotin) and anti-Ki-67 (D, 400x original magnification, 
Streptoavidin-biotin).
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the negative impact of the Bcl-2 expression (15). Studies 
have suggested that positive expressions for Bcl-2 and 
MUM-1 were associated with poor prognosis (16-18). 
However, positive expression for markers such as anti-
CD-10 and Bcl-6 can be associated with favorable prog-
noses (16). In the present case, positive expression for 
CD-10 and Bcl-6 could be observed. Nonetheless, other 
studies have suggested that immunohistochemical sub-
types of DLBCL based on CD-10, MUM-1, and Bcl-6 
have little clinical value (19).
In contrast, Chung et al. (20) suggest that expression 
patterns of the panel of
Germinal-center B-cell (GCB) markers, such as CD-10 
and Bcl-6, and GCB activation markers, such as MUM-1 
by immunohistochemistry can be correlated with the 
prognosis of patients with DLBCL. This study explained 
that the discrepancies regarding the prognostic signifi-
cance of CD-10 or Bcl-6 expression in DLBCL repor-
ted in prior literature is related to the evaluation of these 
two markers (CD-10 and Bcl-6) individually without 
the simultaneous evaluation of activation markers, such 
as MUM-1. Bhattacharyya et al. (21), in a study with 
13 primary oral DLBCLs, show that non-GCB lesions, 
when compared to GCB lesions, may exhibit a poorer 
prognosis. Although the small number of cases and short 
follow-up periods (less than 5 years) are a limitation of 
this study, the authors considered that the stratification 
of DLBCL by immunohistochemistry is possible and 
represents a relatively inexpensive method for the clas-
sification of DLBCL subtypes. In the present case, the 
DLBCL was classified as a subtype of a GCB lesion.
In addition to the prognostic factors, more unfavorable 
results could be observed in older patients, including a 
poor hematologic tolerance to chemotherapy, a higher 
risk for treatment-related toxicity due to altered drug 
metabolism, and a worse immune system. These factors 
lead to a less effective NHL therapy (22,23). Older pa-
tients with aggressive lymphoma present a worse outco-
me than do corresponding younger patients (23). Thus, 
age itself is considered an adverse prognostic factor. Gu-
tierrez et al. (13) reported an increase in the incidence 
of DLBCL in the elderly. Multiple factors, including an 
increase in life expectancy, may well be an important 
factor contributing this increase. In this context, an im-
munological deterioration caused by the aging process 
may well explain the occurrence of EBV-positive DLB-
CL of the elderly in patients without predisposed immu-
nological disorders (11,12).
Conclusion
In the current case, although the patient was of an ad-
vanced age with the presence of hypertensive disease 
and diastolic heart dysfunction, he did undergo an ex-
cellent follow-up treatment. Although doses of R-CHOP 
had been adjusted for the age and heart condition of the 
Discussion
In the present case report, the patient presented an ul-
cer of raised and irregular edges, on the border of the 
hard and soft palate, with a diagnosis of DLBCL-NOS. 
After the physician’s assessment, the mouth was consi-
dered the primary site of the disease, with no other le-
sions appearing in other regions. The patient, at the time 
of the biopsy, was 85 years of age. Although DLBCL 
can occur in a broad age range, the mean age most com-
monly occurs in the 7th and 8th decade of life (2, 3, 6). 
The differential diagnosis was performed by means of 
an incisional biopsy. DLBCL is often mistaken for squa-
mous cell carcinoma and benign or malignant neoplasias 
of the palatal salivary glands. Immediate and accurate 
diagnostic procedures were performed, including immu-
nohistochemical and EBV analyses to avoid delay and 
inappropriate treatment strategies.
The lymphomas are neoplasms that are classified in two 
groups: in Hodgkin’s lymphomas, by the presence of 
the Reed–Sternberg cells, and in non-Hodgkin’s lym-
phomas, by all other lymphoid neoplasms. For the NHL 
group, up to 40% are observed in an extranodal site, and 
2-3% of these extranodal cases may arise primarily in 
the oral cavity and jaws. Studies of oral NHL demons-
trated a major predominance of the DLBCL subtype, 
which accounts for 50% to 68% of all oral NHL (2,7).
In 2008, the International Agency for Research on Cancer 
(IARC) published the 4th edition of the WHO Classifica-
tion of Tumors of Hematopoietic and Lymphoid Tissues 
(8, 10). New subtypes of DLBCL were defined and cases 
that did not present sufficient criteria to classify them 
as distinct variants weredesignated as DLBCL-NOS. In 
addition, EBV-positive DLBCLs in the elderly have also 
been identified as separate entities. These are clinically 
aggressive and occur more often in extranodal rather than 
nodal sites. These lesions also appear to occur most of-
ten at an advanced age, occurringmostly in patients >50 
years of age, with no known immunodeficiency or prior 
lymphoma. These are believed to be related to immu-
nological deterioration derived from the aging process, 
likely due to decreased immune surveillance (11-14).
Therefore, it is necessary to investigate EBV-infection 
in samples diagnosed as DLBCL and in patients over 50 
years of age. However, in the present case, the search for 
the EBV-infection, using both methods ofin situ hybridi-
zation for EBER and immunohistochemistry for LMP1 
protein, proved to be negative.
Immunohistochemical markers have been reported to be 
associated with prognostic effects for DLBCL (8). In the 
present case report, a high proliferation index by means 
of Ki-67 staining could be observed. Positive expression 
of anti-CD20 could also be observed. Moreover, the 
addition of the anti-CD20 antibody rituximab in the che-
motherapy treatment considerably improved the survi-
val rate of patients with DLBCL and proved to eliminate 
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patient, the early diagnosis did prove to be a key contri-
butory factor to this outcome. The extent of tumors in 
the early-stages of DLBCL may well contribute to the 
choice of therapeutic strategy (24), which can have a di-
rect impact on the survival of the patient.
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